Restless legs syndrome

Older baseline recovered October 13 — NCT07179406. University of Alabama at Birmingham plans 50 people in four nonrandomized unmasked groups: RLS/healthy controls, RLS with an existing spinal cord stimulator, RLS scheduled for implantation, and chronic pain with a stimulator but no RLS.

Primary outcomes are changes in H-reflex, SSEP, vibratory evoked potentials and TMS responses within three weeks of consent. This studies neural physiology; it is not a randomized sham comparison of RLS symptoms, sleep, daily function or long-term safety. No results. It is also distinct from NO RLS, NCT07780032, the previously saved 15-person implanted-device safety feasibility program.

The primary registry last updated June 26, 2026 says recruiting, actual start August 4, 2025; estimated primary completion January 31, 2028, final December 31, 2028. A mirror's October 13 synchronization is not a new start/recruitment update or new RLS marketing authorization.

Sources: ClinicalTrials.gov · NCT07179406.

Remaining gaps: Read current canonical scope, shared summaries/state and assigned topic notes. September 5–October 13 overlap preserves the September 12 full-review dates; October 6/9 entries were deduplicated. All pages of each bounded ClinicalTrials.gov query were downloaded, and named records plus selected relevant new/changed protocols were appraised. This is focused partial review, not a worldwide full literature/regulator/safety census; successful full-topic dates must remain unchanged.; Bounded query retrieved 7 records across 1 pages; incidental studies excluded. Named topic records refreshed: 6. Full older evidence, international registries, comprehensive harms and all original conference/podcast recordings remain gaps.; New condition-specific baseline remains incomplete. Selected inherited older pivotal sources and newly recovered formal programs were reviewed, without declaring the preceding 90-day/older trial corpus complete.

Informal-source coverage: Reviewed the original October 7 RLS-algorithm discussion and October 9 patient thread. Drug, stevia and device experiences are not formal new trial results. A TOMAC meta-analysis/corrigendum appears in an October issue, but the original publication date and full correction remain unappraised; the issue date is not treated as new research. No distinct new development rumor was selected. Full SOS/SLEEP presentations and audio remain incomplete.

Full coverage record.

Older clinical context recovered through an October 7 Reddit lead. Silber and colleagues' An Updated Algorithm for the Management of Restless Legs Syndrome was first published May 26, 2026, in the September 2026 issue of Mayo Clinic Proceedings (101:1561–1588; DOI 10.1016/j.mayocp.2026.05.010). It is an expert/literature-based algorithm, not a new randomized trial.

The primary abstract emphasizes iron evaluation and oral/IV options, gabapentinoids as first-line pharmacologic treatment for chronic persistent RLS, dopamine-agonist risks and augmentation, selected low-dose opioid management, and newer approaches including peroneal nerve stimulation and buprenorphine. Special populations are addressed separately.

Only the original indexed abstract and bibliographic dates were reviewed; full dosing/threshold recommendations are not reproduced. The October 7 discussion does not make the May publication new medical news. This provides baseline framing alongside the 2025 AASM guidance; new program efficacy, safety and U.S. access must still be judged separately.

Sources: Primary source 1; Primary source 2; Primary source 3.

Baseline recovery — BRC-002, NCT07224932. University of Colorado plans 60 patients with idiopathic RLS in a masked randomized placebo-controlled phase 2 trial of an oral high-CBD botanical extract containing less than 0.3% THC.

Primary is safety/tolerability based on adverse events, examinations, vital signs and laboratory monitoring; secondary day-20 outcomes include IRLS symptoms, sleep quality, daytime sleepiness, fatigue, cognition and mood. A device-derived sleep-quality score is not proof of restored REM/deep sleep architecture. No results are posted.

The October 8 registry still says not yet recruiting, with November 1, 2026 estimated start, March 14, 2028 estimated primary completion, and June 1, 2028 final completion. First registration was November 5, 2025; this is baseline program recovery, not a brand-new October trial announcement. General CBD commercial availability does not establish FDA approval for RLS.

Sources: Primary source 1.

Baseline context — NO RLS, NCT07780032. This University of Alabama at Birmingham/NINDS-supported first-in-indication feasibility study plans 15 people with severe treatment-refractory primary RLS, implanted with the Saluda Evoke spinal-cord stimulation system and followed for 24 months.

Primary is device-, stimulation- and procedure-related adverse events. Symptoms, function and other patient outcomes are secondary. This uncontrolled single-centre design cannot establish superiority over sham, drugs, iron or noninvasive peroneal stimulation; an implanted spinal-cord device is a materially different intervention from Nidra.

Registered August 21, 2026, the October 9 record remains not yet recruiting. Start is estimated October 2027, primary completion October 2033, final October 2034—all month precision, not promises. No results or RLS-specific U.S. marketing authorization are established by this registry.

Sources: Primary source 1.

Remaining gaps: New condition baseline remains incomplete. Reviewed inherited hub, preceding 90-day development leads and selected older pivotal/contextual sources; October 6 findings deduplicated.; 93 named NCT records across the ten topics and ten discovery queries downloaded successfully through the ClinicalTrials.gov public API. Download is not a claim that all fields/safety/results were exhaustively appraised.; Focused review only. Do not advance full successful-check timestamps or label incomplete remaining searches as no news.; All seven matches in bounded RLS discovery downloaded; selected relevant records screened. Selected older trial/guideline anchors added; full drug/iron labeling, safety, pediatric/pregnancy and older trial corpus remain incomplete. Venous-ablation full methods/harms gap persists; no cure conclusion.

Informal-source coverage: Original October 7 RLS algorithm thread led to a verified May 26 original publication. Individual October device/medication experiences are not trial efficacy. Full SLEEP/SOS recordings and podcast interviews remain incomplete.

Full coverage record.

Source/event date: September 16, 2026. Evidence: new registration recovered during sleep baseline. A French open-label randomized phase 2 study plans 66 adults with drug-resistant severe RLS on stable background therapy, comparing immediate IV ferric carboxymaltose with treatment delayed 12 weeks. Primary: IRLSSG severity score through week12; sleep, daytime symptoms, quality of life, iron and augmentation measures continue through week24. NOT_YET_RECRUITING; October2026 estimated start, April2029 primary and October2030 final completion. No effect/safety estimates. This extends the saved device-only research baseline; it does not establish a new IV-iron benefit, U.S. RLS indication or confirmed start.

ClinicalTrials.gov · NCT07822607 · ClinicalTrials.gov · NCT07822607

Historical baseline addition reviewed October 6, 2026. NCT07675109 recruits 20 planned adults to optimize extended-duration TOMAC. It uses a participant-masked crossover/pseudo-randomized sequence of three device settings in the final six weeks, with total assessments over 12 weeks. Primary: RLS-related awakenings/night; symptoms, sleep and quality of life are secondary. Actual start June8,2026, estimated primary completion December2026 and final June2027; no results. This is optimization of investigational extended-duration therapy, not proof that an existing prescription device’s indication includes the new setting. Small selected cohorts and comparisons with baseline cannot establish broad long-term benefit or safety.

ClinicalTrials.gov · NCT07675109 · ClinicalTrials.gov · NCT07675109

Source/event date: September 16, 2026; abstract recovered October 6. Evidence: uncontrolled pre–post observational study. In 160 consecutive patients with symptomatic chronic venous insufficiency treated in 2022–2023, median RLS severity declined 21→7 and sleep-quality score 6→4 within three months after radiofrequency ablation (both P<.001). Excessive daytime sleepiness prevalence did not significantly change (7.5%→5.6%, P=.317).

There was no untreated/sham comparator; regression to the mean, expectation and changes in venous discomfort can explain part of the association. Full methods, formal RLS confirmation, concomitant medication changes and procedural harms were not appraised; confidence intervals and safety counts were absent from the abstract. This does not establish venous ablation as a general RLS treatment or create a U.S. RLS indication. The previously saved full-methods gap remains despite clearer abstract-level context.

journals.sagepub.com · article